254 related articles for article (PubMed ID: 31614438)
1. Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides.
Aung-Htut MT; McIntosh CS; Ham KA; Pitout IL; Flynn LL; Greer K; Fletcher S; Wilton SD
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614438
[TBL] [Abstract][Full Text] [Related]
2. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
[TBL] [Abstract][Full Text] [Related]
3. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
4. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2011 Aug; 11(4):259-75. PubMed ID: 21453280
[TBL] [Abstract][Full Text] [Related]
5. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
6. Invention and Early History of Exon Skipping and Splice Modulation.
Lim KRQ; Yokota T
Methods Mol Biol; 2018; 1828():3-30. PubMed ID: 30171532
[TBL] [Abstract][Full Text] [Related]
7. Optimizing splice-switching oligomer sequences using 2'-O-methyl phosphorothioate chemistry.
Adkin C; Fletcher S; Wilton SD
Methods Mol Biol; 2012; 867():169-88. PubMed ID: 22454061
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.
Adams AM; Harding PL; Iversen PL; Coleman C; Fletcher S; Wilton SD
BMC Mol Biol; 2007 Jul; 8():57. PubMed ID: 17601349
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake.
Schmajuk G; Sierakowska H; Kole R
J Biol Chem; 1999 Jul; 274(31):21783-9. PubMed ID: 10419493
[TBL] [Abstract][Full Text] [Related]
10. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
11. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
12. Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.
Li Z; Li Q; Han L; Tian N; Liang Q; Li Y; Zhao X; Du C; Tian Y
Oncol Rep; 2016 Feb; 35(2):1013-9. PubMed ID: 26718027
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide induction of progerin in human myogenic cells.
Luo YB; Mitrpant C; Adams AM; Johnsen RD; Fletcher S; Mastaglia FL; Wilton SD
PLoS One; 2014; 9(6):e98306. PubMed ID: 24892300
[TBL] [Abstract][Full Text] [Related]
14. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.
Singh NN; Luo D; Singh RN
Methods Mol Biol; 2018; 1828():415-437. PubMed ID: 30171557
[TBL] [Abstract][Full Text] [Related]
15. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
16. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.
Karras JG; McKay RA; Dean NM; Monia BP
Mol Pharmacol; 2000 Aug; 58(2):380-7. PubMed ID: 10908306
[TBL] [Abstract][Full Text] [Related]
17. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
[TBL] [Abstract][Full Text] [Related]
18. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
[TBL] [Abstract][Full Text] [Related]
19. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
Guncay A; Yokota T
Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
